Bridge Capture™ by Genomill represents a major leap forward in liquid biopsy diagnosis
Turku, Finland — 20.5.2024. The new method will enable cost-efficient, rapid, and sensitive molecular precision diagnostics for cancer. Tissue biopsies have traditionally been the mainstay for diagnosing cancer, but now, liquid biopsies, drawn from a simple blood sample, are emerging as a less invasive option. While liquid biopsies offer advantages like easier disease monitoring and […]
Genomill and Finland’s Cancer Research Flagship iCAN Partner To Improve Cancer Detection Using an Extensive Biobank Cohort
Helsinki, Finland – June 13, 2023 – Genomill and iCAN, the Finnish national cancer research flagship project, signed a partnership aiming to improve the detection of trace tumour DNA from thousands of biobank samples.
Genomill appoints former foundation medicine executive and plans to present unmatched data at PMWC
Seminal presentation of first analytical validation data scheduled for june 30
Genomeweb: Genomill Health Positioning Geno1 Technology to Improve Liquid Biopsy Sequencing
NEW YORK – After closing an investment round last month for an undisclosed sum, Finnish firm Genomill Health is aiming to broaden adoption of its Geno1 technology, a barcoding-based method that it believes can enhance sequencing accuracy and lower costs and turnaround time for applications with high sensitivity and efficiency demands like liquid biopsy. The […]
Genomill Health closes investment round to expand beta-testing with liquid biopsy players
Genomill Health closes a financing round led by a deep tech VC Voima Ventures to expand its novel and disruptive technology, focusing on efficient use of NGS (next generation sequencing) in liquid biopsies for cancer diagnostics.